Lipid transfer protein activities in subjects with impaired glucose tolerance

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 2, 2007, Pages 237-243

  Julius, Ulrich ^a   Jauhiainen, Matti ^b   Ehnholm, Christian ^b   Pietzsch, Jens ^c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

Cholesterol ester transfer protein; Impaired glucose tolerance; Oral fat loading test; Oral glucose tolerance test; Phospholipid transfer protein

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID TRANSFER PROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; POSTPRANDIAL STATE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADOLESCENT; ADULT; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CHOLESTEROL ESTER TRANSFER PROTEINS; DIET; DYSLIPIDEMIAS; FASTING; GLUCOSE INTOLERANCE; HUMANS; LIPOPROTEINS; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; POSTPRANDIAL PERIOD;

EID: 33847116237     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2007.032     Document Type: Article

References (48)

1. Ceriello A. Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. Am Heart J 2004;147:803-7.
2. Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis 1998;137(Suppl):S65-73.
3. Gerich JE. Postprandial hyperglycemia and cardiovascular disease. Endocr Pract 2006;12(Suppl 1):47-51.
4. Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004;164:2147-55.
5. Gao W, Qiao Q, Tuomilehto J. Post-challenge hyperglycaemia rather than fasting hyperglycaemia is an independent risk factor of cardiovascular disease events. Clin Lab 2004;50:609-15.
6. Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 2003;46(Suppl 1):M17-21.
7. Schnell O, Standl E. Impaired glucose tolerance, diabetes, and cardiovascular disease. Endocr Pract 2006;12(Suppl 1):16-9.
8. Zhang YF, Hong J, Zhan WW, Li XY, Gu WQ, Yang YS, et al. Hyperglycaemia after glucose loading is a major predictor of preclinical atherosclerosis in nondiabetic subjects. Clin Endocrinol (Oxf) 2006;64:153-7.
9. Petersen JL, McGuire DK. Impaired glucose tolerance and impaired fasting glucose - a review of diagnosis, clinical implications and management. Diab Vasc Dis Res 2005;21:9-15.
10. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 2001;243:447-53.
11. Rye KA, Clay MA, Barter PJ. Remodelling of high density lipoproteins by plasma factors. Atherosclerosis 1999;145:227-38.
12. Tall AR, Krumholz S, Olivecrona T, Deckelbaum RJ. Plasma phospholipids transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res 1985;26:842-51.
13. Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 1993;268:4032-6.
14. Tu A-Y, Nishida HI, Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J Biol Chem 1993;268:23098-105.
15. Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999;103:907-14.
16. Jaari S, van Dijk KW, Olkkonen VM, van der Zee A, Metso J, Havekes L, et al. Dynamic changes in mouse lipoproteins induced by transiently expressed human phospholipid transfer protein (PLTP): importance of PLTP in prebeta-HDL generation. Comp Biochem Physiol B Biochem Mol Biol 2001;128:781-92.
17. Oka T, Kujiraoka T, Ito M, Egashira T, Takahashi S, Nanjee MN, et al. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res 2000;41:1651-7.
18. Karkkainen M, Oka T, Olkkonen VM, Metso J, Hattori H, Jauhiainen M, et al. Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J Biol Chem 2002;277:15413-8.
19. Bruce C, Chouinard RA Jr, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 1998;18:297-330.
20. The Diabetes Prevention Program Research Group. Lipid, lipoproteins, C-reactive protein, and hemostatic factors at baseline in the diabetes prevention program. Diabetes Care 2005;28:2472-9.
21. Nauck MA, Meier JJ, Wolfersdorff AV, Tillil H, Creutzfeldt W, Kobberling J. A 25-year follow-up study of glucose tolerance in first-degree relatives of type 2 diabetic patients: association of impaired or diabetic glucose tolerance with other components of the metabolic syndrome. Acta Diabetol 2003;40:163-72.
22. Matthews DR, Hosker JP, Rudenski AS, Nayler BA, Treac DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412-9.
23. Haffner SM, Kennedy E, Gonzales C, Stern MP, Miettienen H. A prospective analysis of the HOMA model: the Mexico City Diabetes Study. Diabetes Care 1996;19:1138-41.
24. Jänis MT, Siggins S, Tahvanainen E, Vikstedt R, Silander K, Metso J, et al. Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample. J Lipid Res 2004;45:2303-9.
25. Pietzsch J, Julius U, Nitzsche S, Hanefeld M. In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes 1998;47:1928-34.
26. Friedewald WT, Levi RI, Fredrickson DS. Estimation of the concentration of low density lipoproteins cholesterol in plasma without use of the ultracentrifuge. Clin Chem 1972;18:499-502.
27. Syvänne M, Taskinen M-R. Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus. Lancet 1997;350(Suppl 1):20-23.
28. Frayn KN. Insulin resistance and lipid metabolism. Curr Opin Lipidol 1993;4:197-204.
29. Pietzsch J, Julius U, Kirch C, Fischer S, Hanefeld M. Very low density lipoprotein (VLDL) overproduction is maximally expressed in early insulin resistant states. Ann NY Acad Sci 1999;892:319-22.
30. Kissebah AH, Alfarsi S, Evans DJ, Adams PW. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein-B kinetics in non-insulin-dependent diabetes mellitus. Diabetes 1982;31:217-25.
31. Hill SA, Thomson C, McQueen MJ. Cholesteryl ester transfer protein mutations, protein activity and HDL-cholesterol concentration. Clin Chem Lab Med 1998;36:629-32.
32. Ambrosch A, Mühlen I, Kopf D, Augustin W, Dierkes J, König W, et al. LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and healthy subjects. Diabetes Care 1998;21:2077-84.
33. Murdoch SJ, Carr MC, Hokanson JE, Brunzell JD, Albers JJ. PLTP activity in premenopausal women. Relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance. J Lipid Res 2000;41:237-44.
34. Colhoun HM, Taskinen MR, Otvos JD, Van Den Berg P, O'Connor J, Van Tol A. Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes. Diabetes 2002;51:3300-5.
35. Murdoch SJ, Carr MC, Kennedy H, Brunzell JD, Albers JJ. Selective and independent associations of phospholipid transfer protein and hepatic lipase with the LDL subfraction distribution. J Lipid Res 2002;43:1256-63.
36. Cheung MC, Knopp RH, Retzlaff B, Kennedy H, Wolfbauer G, Albers JJ. Association of plasma phospholipid transfer protein activity with IDL and buoyant LDL: impact of gender and adiposity. Biochim Biophys Acta 2002;1587:53-9.
37. Dullaart RP, De Vries R, Scheek L, Borggreve SE, Van Gent T, Dallinga-Thie GM, et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest 2004;64:205-15.
38. Borggreve SE, De Vries R, Dullaart RP. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003;33:1051-69.
39. van Tol A. Phospholipid transfer protein. Curr Opin Lipidol 2002;13:135-9.
40. Dullaart RP, van Tol A. Role of phospholipid transfer protein and prebeta-high density lipoproteins in maintaining cholesterol efflux from Fu5AH cells to plasma from insulin-resistant subjects. Scand J Clin Lab Invest 2001;61:69-74.
41. Rashid S, Barrett PH, Uffelman KD, Watanabe T, Adeli K, Lewis GF. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler Thromb Vasc Biol 2002;22:483-7.
42. Guerin M, Le Goff W, Lassel TS, Van Tol A, Steiner G, Chapman MJ. Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001;21:282-8.
43. Syeda F, Senault C, Delplanque B, Le Roy B, Thaminy A, Gripois D, et al. Postprandial variations in the cholesteryl ester transfer protein activity, phospholipid transfer protein activity and plasma cholesterol efflux capacity in normolipidemic men. Nutr Metab Cardiovasc Dis 2003;13:28-36.
44. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerosis cardiovascular disease. Nat Rev Drug Discov 2005;4:193-205.
45. Barter PJ, Kastelein JJ. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 2006;47:492-9.
46. Albers JJ, Cheung MC. Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism. Curr Opin Lipidol 2004;15:255-60.
47. Desrumaux CM, Mak PA, Boisvert WA, Masson D, Stupack D, Jauhiainen M, et al. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J Lipid Res 2003;44:1453-61.
48. O'Brien KD, Vuletic S, McDonald TO, Wolfbauer G, Lewis K, Tu AY, et al. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation 2003;108:270-4.